Facer SIGNED
The First Cell Culture Platform that Enables Affordable Cell Therapies at a Large Scale
Total Cost €
0EC-Contrib. €
0Partnership
0Views
0Facer project word cloud
Explore the words cloud of the Facer project. It provides you a very rough idea of what is the project "Facer" about.
Project "Facer" data sheet
The following table provides information about the project.
| Coordinator |
AGLARIS LIMITED
Organization address contact info |
| Coordinator Country | United Kingdom [UK] |
| Total cost | 2˙051˙000 € |
| EC max contribution | 1˙435˙700 € (70%) |
| Programme |
1. H2020-EU.3. (PRIORITY 'Societal challenges) 2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs) 3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies) |
| Code Call | H2020-SMEInst-2018-2020-2 |
| Funding Scheme | SME-2 |
| Starting year | 2019 |
| Duration (year-month-day) | from 2019-04-01 to 2020-09-30 |
Partnership
Take a look of project's partnership.
| # | ||||
|---|---|---|---|---|
| 1 | AGLARIS LIMITED | UK (STEVENAGE) | coordinator | 1˙435˙700.00 |
Map
Project objective
Cell therapy has shown promising results for treating and curing a large range of diseases, from cancer to diabetes. The principles of cell therapy are easy to describe: cells (possibly modified) are injected into patients. Cell therapy is now a reality in Europe: in August 2018 the first two treatments for patients with blood cancer were approved; more of them are about to successfully conclude the approval path. What hinders the large-scale uptake of cell therapy is its costs: culturing enough cells of high quality requires specialised personnel and infrastructure, which only a few centres can afford. The market asks for a scalable cell culture platform that can produce large quantities of high quality cells at much lower costs than done nowadays. To address this need, we have developed the Facer – the first fully-autonomous cell culture platform. The Facer can manufacture billions of high-quality cells starting from the small quantity (about 500,000 cells) of a tissue biopsy without the need of human intervention, thanks to a unique patented iterative process. Our product is at TRL 7; its performances, in terms of quality and costs, are superior to any competitor commercially available. We have developed the Facer over the course of 5 years thanks to cash investments of over €3 million. In the Phase 2 project we will finalise the product, perform a validation with external partners, gain the CE marking (our product is not a medical device), and find a distributor and a launching customer. We will initially tackle the European market to then expand globally once that the local regulatory barriers are overcome. In 2024, after 5 years from the first sale, our turnover will surpass the €60 million and our EBITDA will be over €36 million. Our innovation can enable affordable cell therapies at a large scale and change the life of millions of patients who suffer from diseases that have been deemed 'incurable' so far.
Publications
| year | authors and title | journal | last update |
|---|---|---|---|
| 2019 |
Mireia Ruiz Development of an autonomous platform for CAR T-cell manufacturing published pages: , ISSN: , DOI: |
National Instrument case – Real world applications | 2020-04-15 |
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "FACER" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "FACER" are provided by the European Opendata Portal: CORDIS opendata.
